Rheumatology–Musculoskeletal Disorders

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2018. Fujiwara S et al. – Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: Retrospective chart review
2018. Guirant L et al. – Health-related quality of life during the first year after a hip fracture: Results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS)
2017. Dalén J et al. – Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
2017. Svedbom A et al. – Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: Results from the ICUROS
2017. Svedbom A et al. – Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS
2017. Guyot P et al. – Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies
2017. Weijers L et al. – Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
2017. Wang X et al. – A systematic literature review of time to return to work and narcotic use after lumbar spinal fusion using minimal invasive and open surgery techniques
2017. Alemao E et al. – Comparison of cardiovascular risk algorithms in patients with vs. without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis
2017. Svedbom A et al. Persistence with golimumab in immune-mediated rheumatic diseases: A systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
2017. Kerr C et al. – The importance of physical function to people with osteoporosis
2017. Bergrath E et al. – Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: Systematic literature review and network meta-analysis
2017. Maiese BA et al. – Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) plus other IV analgesics or IV opioid monotherapy for postoperative pain
2017. Svedbom A et al. – Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
2016. Vieira MC et al. – Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: Results from a network meta-analysis
2016. Meunier J et al. – Work-related discussions between French rheumatologists and their rheumatoid arthritis patients
2016. Jürisson M et al. – Quality of life, resource use, and costs related to hip fracture in Estonia
2016. Jansen JP et al. – Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis
2016. Dalén J et al. – Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
2016. Gaultney J et al. – Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy
2016. Alemao E et al. – Cardiovascular risk factor management in patients with RA compared to matched non-RA patients
2016. Karabis A et al. – High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: Meta-analysis and implications
2015. Svedbom A et al. – Is dibotermin alfa a cost-effective substitute for autologous iliac crest bone graft in single level lumbar interbody spine fusion?
2015. Buckley F et al. – Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis
2015. van Walsem A et al. – Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis
2014. Baron R et al. – Improving the primary care physicians’ decision making for fibromyalgia in clinical practice: Development and validation of the Fibromyalgia Detection (FibroDetect®) screening tool
2014. Dimai HP et al. – Epidemiology of distal forearm fractures in Austria between 1989 and 2010
2014. Kanis JA et al. – The osteoporosis treatment gap
2014. Ariza R et al. – [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain.]
2014. Svedbom A et al. – Epidemiology and economic burden of osteoporosis in Switzerland
2014. Lambert J et al. – Linguistic validation into 20 languages and content validity of the Rheumatoid Arthritis-Specific Work Productivity and Activity Impairment questionnaire
2014. Kim K et al. – Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
2013. Hernlund E et al. – Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
2013. Svedbom A et al. – EU Review Panel of IOF. Osteoporosis in the European Union: A compendium of country-specific reports
2013. Dimai HP et al. – Epidemiology of proximal humeral fractures in Austria between 1989 and 2008
2013. Kanis JA et al. – The osteoporosis treatment gap in Romania
2013. Borgström F et al. – The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture
2013. Svedbom A et al. – Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: A UK cost-effectiveness analysis
2012. Guyot P et al. – Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
2012. Stam W et al. – Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison
2012. Breuil V et al. – Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women
2011. Guyot P et al. – Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: A network meta-analysis
2011. Jansen JP et al. – Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway
2011. Jansen JP et al. – The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: A network meta-analysis
2010. Serra E et al. – Development of the Fibromyalgia Burden Assessment: Measuring the multifaceted burden of fibromyalgia
2010. Zlateva G et al. – Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care
2010. Bergman GJ et al. – Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: A meta-analysis
2010. Le Gal M et al. – Linguistic validation of six patient-reported outcomes instruments into 12 languages for patients with fibromyalgia
2010. Bergman GJ et al. – Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
2010. Jansen JP et al. – Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis
2009. Jansen JP et al. – Prevention of vertebral fractures in osteoporosis: Mixed treatment comparison of bisphosphonate therapies
2008. Roux C et al. – Inverse relationship between vertebral fractures and spine osteoarthritis in postmenopausal women with osteoporosis
2008. Jansen JP et al – Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands
2005. Acquadro C et al. – Linguistic validation of the Cardiff Wound Impact Schedule into French, German and US English

Posters & Presentations

2017. ACR/ARHP Annual Meeting – Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
2017. ACR/ARHP Annual Meeting – Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
2017. ACR/ARHP Annual Meeting – Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis
2017. ACR/ARHP Annual Meeting – Preliminary results related to psychometric features of a new methotrexate (MTX)-specific adherence tool for use in the management of patients with rheumatoid arthritis (RA): Results from an online patient community
2017. ISPOR European Congress – Adherence issues in rheumatoid arthritis treatment: How can acceptance measurement help understanding patients’ concerns and working on solutions?
2017. ISPOR Latin America Conference – Secukinumab shows greater symptomatic improvement versus etanercept in psoriatic arthritis: Comparative effectiveness up to 24 weeks assessed by matching-adjusted indirect comparison
2017. ISPOR Latin America Conference – Secukinumab shows greater symptomatic improvement versus infliximab in psoriatic arthritis: Comparative effectiveness up to 1 year assessed by matching-adjusted indirect comparisons
2017. ISPOR Latin America Conference – Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison: An analysis based on all pivotal phase 3 clinical trial data
2017. ISPOR Latin America Conference – Secukinumab provides greater symptomatic improvement versus adalimumab in psoriatic arthritis: Comparative effectiveness up to 48 weeks assessed by two matching-adjusted indirect comparisons
2017. JOSKAS – Linguistic validation of the Patient’s Knee Implant Performance (PKIP), pre- and post-surgery versions, into Japanese
2017. EULAR Annual Congress – Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by Matching-Adjusted Indirect Comparison using pivotal phase 3 clinical trial data
2017. EULAR Annual Congress – Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by Matching-Adjusted Indirect Comparison using pivotal phase 3 clinical trial data
2017. EULAR Annual Congress – Early response to certolizumab pegol in rheumatoid arthritis predicts outcome: Data from a prospective observational study
2017. European Calcified Tissue Society Congress – Risk of subsequent fracture after osteoporosis-related fractures: Results from a real-world German sick fund analysis
2017. AMCP Managed Care Specialty Pharmacy Annual Meeting – Secukinumab for the treatment of psoriatic arthritis: Comparative effectiveness versus adalimumab using a Matching-Adjusted Indirect Comparison
2017. AMCP Managed Care Specialty Pharmacy Annual Meeting – Secukinumab for the treatment of psoriatic arthritis: Comparative effectiveness versus infliximab using a matching-adjusted indirect comparison
2016. ACR/ARHP Annual Meeting – Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
2016. ACR/ARHP Annual Meeting – Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
2016. ACR/ARHP Annual Meeting – Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
2016. ISPOR European Congress – Budget Impact of Apremilast for Active Psoriatic Arthritis in the UK
2016. APLAR Congress – Secukinumab for Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using a Matching-Adjusted Indirect Comparison
2016. APLAR Congress – Secukinumab for Psoriatic Arthritis: Comparative Effectiveness Results versus Etanercept Up To 24 Weeks Using a Matching-Adjusted Indirect Comparison
2016. Spondylarthritides Congress – Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
2016. Spondylarthritides Congress – Secukinumab for the Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using a Matching-Adjusted Indirect Comparison
2016. EULAR Annual Congress – Cost per Response for Abatacept Compared with Adalimumab in the Treatment of Patients with Rheumatoid Arthritis Based on Anti-Citrullinated Protein Antibody Titres in Italy, Spain and Canada
2016. EULAR Annual Congress – Tofacitinib Versus Biologic Treatments in Moderate to Severe Rheumatoid Arthritis Patients who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
2016. EULAR Annual Congress – First and Second Line Treatment Persistence Among Patients with Immune Mediated Rheumatoid Disease Treated with Subcutaneous TNF-Alpha Inhibitors
2016. ISPOR Annual International Meeting – Anti-CCP2 Quartile Comparison of the Cost per Response for Abatacept Compared to Adalimumab Based on Sample in the US
2016. WCO-IOF-ESCEO Meeting – Quality of Life up to 18 Months after Distal Forearm Fracture: Results from the ICUROS
2016. WCO-IOF-ESCEO Meeting – Accumulated Quality of Life Loss 36 Months after Vertebral and Distal Forearm Fracture: Results from ICUROS in Lithuania
2015. ISPOR European Congress – Methotrexate Adherence Questionnaire: A New Tool to Assess Adherence in Patients Treated with Methotrexate
2015. ISPOR European Congress – Patient Characteristics and Disease Burden of Osteoporosis in Post-Menopausal Women at Risk of Fracture in Germany
2015. ISPOR European Congress – PRO Claims in Fibromyalgia: A Review of the Labels of Products Approved by the FDA and the EMA
2015. ISPOR European Congress – Cost-Effectiveness of Apremilast in Psoriatic Arthritis in Scotland
2015. ISPOR European Congress – Cost-Effectiveness of Abatacept Compared to Adalimumab in Italy Based on a Head-to-Head Outcomes Study in Rheumatoid Arthritis
2014. Mediterranean Congress of Rheumatology – Comparative Efficacy and Safety of Diclofenac Versus Naproxen in Pain Relief: Results of a Systematic Literature Review and Network Meta-Analysis
2014. ISPOR Annual International Meeting – Comparative Efficacy of Novel DMARDs as Monotherapy in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional DMARDs – A Network Meta-Analysis
2013. ISPOR European Congress – Cost-Minimization Analysis of Subcutaneous Abatacept in the Treatment of Rheumatoid Arthritis in Spain
2013. ACR/AHRP Annual Meeting – Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
2013. ACR/AHRP Annual Meeting – Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
2012. ACR/AHRP Annual Meeting – Comparative efficacy of biologics as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to conventional DMARDs: A network meta-analysis
2012. ISPOR European Congress – Detecting Potential Fibromyalgia Patients in Primary Care Setting: Validation of the FibroDetect Screening Tool
2012. ISPOR European Congress – Comparative Efficacy of Tocilizumab and Anti-TNF Biologic Monotherapies on Patient-Reported Outcomes (PROs) in RA Patients Who Have Shown an Inadequate Response to Conventional DMARDS (DMARD-IR): A Network Meta-Analysis
2012. ISPOR European Congress – Comparing the efficacy and safety of biologics for the treatment of rheumatoid arthritis patients: a network meta-analysis
2012. ISPOR European Congress – Comparing the Efficacy and Safety of Biologics for the Treatment of Rheumatoid Arthritis Patients: A Network Meta-Analysis
2012. ISCB Annual Conference – Applying partial least squares discriminant analysis (PLS-DA) for optimisation of decision rules based on complex patient-reported data: creation of the FibroDetect® scoring method
2012. EULAR Annual European Congress – Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs. A network meta-analysis
2012. EULAR Annual European Congress – Meta-analysis of joint structural deterioration over time in minimally treated rheumatoid arthritis patients
2012. ECCEO-IOF European Congress – Indirect comparison of bazedoxifene vs. oral bisphophonates for the prevention of nonvertebral fractures in high-risk post-menopausal osteoporosis population
2011. ISPOR European Congress – Mixed Treatment Comparison of Biologic Agents in Patients with Rheumatoid Arthritis Who Have responded Inadequately to Methotrexate Therapy in the United Kingdom
2011. ISPOR Annual International Meeting – Cost-Effectiveness of Abatacept in Comparison with Other Biologic Therapies for the Treatment of Moderate to Severe Active Rheumatoid Arthritis Patients Who Have Failed to Methotrexate Based Treatment at Essalud in 2010
2011. ISPOR Annual International Meeting – Content Validity and Health Care Systems: A Case Study
2010. ISPOR European Congress – Use of Qualitative Research to Identify Determinants of Persistence for Anti-Osteoporotic Treatments
2010. ISPOR European Congress – Indirect Treatment Comparison to Compare Efficacy in Health Assessment Questionnaire (HAQ) Score for Biologic Agents with Methotrexate in Patients with Rheumatoid Arthritis and Active Disease Despite Methotrexate Therapy
2010. ISPOR European Congress – The Cost-Effectiveness of Abatacept in Combination with Methotrexate for the Treatment of Patient with Active Rheumatoid Arthritis after an Inadequate Response to Methotrexate in the United Kingdom
2009. ISOQOL Annual Conference – Translating a PRO Measure into 3 Oral Languages: The Use of the HAQ-DI in South Africa
2009. ISPOR European Congress – Development of a Tool to help in the Early Detection of Fibromyalgia (FM) in General Practice in Europe
2009. ISPOR European Congress – Use of Qualitative Research to Elicit Patient-Reported Outcome Approaches in Osteoporosis
2009. ISPOR European Congress – Item Reduction and Validation of a New Adherence Questionnaire in Osteoporotic Post-Menopausal Women: The Adherence Evaluation of Osteoporosis Treatment (ADEOS) Questionnaire
2009. ISPOR European Congress – Fibromyalgia Fatigue – Development of a Conceptual Model Based on Qualitative Patient Interviews
2008. ISPOR European Congress – Qualitative Steps for the Development of a Questionnaire Assessing the Burden of Fibromyalgia on Patients’ Daily Lives
2008. ISPOR European Congress – Development of a Specific Tool to Evaluate Women’s Adherence to Osteoporosis Treatment
2008. ISPOR European Congress – Linguistic Validation of Six Quality of Life Questionnaires for Fibromyalgia Patients in Twelve Languages
2008. ISPOR Annual International Meeting – Bayesian Cost-Effectiveness Analysis of Treatment of Ankylosing Spondylitis
2008. ISPOR Annual International Meeting – Efficacy of Cox-2 Selective NSAIDS, Non-Selective NSAIDS, and Acetaminophen in Osteoarthritis: A Bayesian Mixed Treatment Comparison